Rezolute/$RZLT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Rezolute
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
- Ticker
- $RZLT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 58
- Headquarters
- Redwood City, United States
- Website
- www.rezolutebio.com
Rezolute Metrics
BasicAdvanced
$407M
-
-$0.75
-
-
Price and volume
Market cap
$407M
52-week high
$11.46
52-week low
$1.07
Average daily volume
1.5M
Financial strength
Current ratio
9.916
Quick ratio
9.511
Long term debt to equity
0.001
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-81.003
Management effectiveness
Return on assets (TTM)
-39.77%
Return on equity (TTM)
-66.85%
Valuation
Price to book
4.37
Price to tangible book (TTM)
4.37
Price to free cash flow (TTM)
-6.13
Free cash flow yield (TTM)
-16.31%
Free cash flow per share (TTM)
-0.633
Growth
Earnings per share change (TTM)
-18.73%
3-year earnings per share growth (CAGR)
-12.05%
10-year earnings per share growth (CAGR)
-32.65%
What the Analysts think about Rezolute
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Analyst projections of the future price of Rezolute stock.
Bulls say / Bears say
In the small Phase 3 upLIFT tumour study, 7 of the first 8 participants met the glucose-reduction response criterion, and each also stopped intravenous glucose. If the full 16-person study confirms this signal, it could support a route towards treatment of tumour-related hyperinsulinism. (Rezolute)
After reviewing additional congenital HI data, the FDA recommended a pre-BLA meeting, keeping a possible regulatory route open despite the trial miss. That is a meaningful next step, though it is not an endorsement of approval. (Rezolute)
The congenital HI study’s open-label extension has retained most participants, with the company reporting improved glucose control alongside lower use of background treatments. This offers a potential sign of lasting benefit, although the extension has no placebo comparison. (Rezolute)
The pivotal sunRIZE trial did not meet its primary endpoint or key secondary endpoint at the planned final assessment. That leaves the main congenital HI programme without a successful pivotal result. (Rezolute)
The FDA has not said ersodetug is approvable for congenital HI; it said that would be decided only through a formal application review. The next steps and evidence needed therefore remain uncertain despite the proposed pre-BLA meeting. (Rezolute)
Rezolute has no meaningful product revenue and used $64.6 million of cash in operations in FY2026. Its $107.8 million of cash and investments at June 2026 is finite, and the company says it expects to need further external capital before it can generate revenue, putting shareholders at risk of dilution. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
Rezolute Financial Performance
Revenues and expenses
Rezolute Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Rezolute
Fund name | Fund size | $RZLT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.